TD Cowen Maintains Buy on AnaptysBio, Lowers Price Target to $70

Benzinga · 2d ago
TD Cowen analyst Joseph Thome maintains AnaptysBio (NASDAQ:ANAB) with a Buy and lowers the price target from $75 to $70.